Drugs / LY2428757
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 missed | ||||||
| Phase 1 | NCT00853151 | Feb 2009 → May 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Missed primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00804986 | Dec 2008 → Jan 2010 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2428757 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00853151 ↗ |
| Route | Subcutaneous | “Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks.” NCT00804986 ↗ |